Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
Research

Antibodies against MERS Coronavirus in Dromedary Camels, United Arab Emirates, 2003 and 2013

Benjamin Meyer, Marcel A. Müller, Victor M. Corman, Chantal B.E.M. Reusken, Daniel Ritz, Gert-Jan Godeke, Erik Lattwein, Stephan Kallies, Artem Siemens, Janko van Beek, Jan F. Drexler, Doreen Muth, Berend-Jan Bosch, Ulrich Wernery, Marion P.G. Koopmans, Renate Wernery, and Christian DrostenComments to Author 
Author affiliations: University of Bonn Medical Centre, Bonn, Germany (B. Meyer, M.A. Müller, V.M. Corman, D. Ritz, S. Kallies, A. Siemens, J.F. Drexler, D. Muth, C. Drosten); National Institute for Public Health and the Environment, Bilthoven, the Netherlands. (C.B.E.M. Reusken, G.-J. Godeke, J. van Beek, M.P.G. Koopmans); Erasmus Medical Centre, Rotterdam, the Netherlands (C.B.E.M. Reusken, J.F. Drexler, M.P.G. Koopmans); EUROIMMUN AG, Lübeck, Germany (E. Lattwein); Utrecht University, Utrecht, the Netherlands (B.-J. Bosch); Central Veterinary Research Laboratory, Dubai, United Arab Emirates (U. Wernery, R. Wernery)

Main Article

Table 1

Validation of serologic assays for coronaviruses with differentially reactive dromedary serum samples, United Arab Emirates, 2013*

Serum no. rIFA titer†‡
 Protein array (RFU) ‡§
vIFA titer†‡
 Neutralization test titer¶#
MERS-S OC43-S MERS-S1 OC43-S1 SARS-S1 MERS-CoV MERS-CoV BCoV
1 – – 2,555 3,868 2,606 – – 40
2 – 320 2,770 18,896 2,776 – – 80
3 – 640 3,950 65,535 2,751 – – 160
4 320 – 65,535 3,921 1,726 640 40 –
5 >10,240 320 65,535 7,247 2,306 >5,120 2,560 160
6 5,120 640 65,535 5,069 2,098 2,560 640 160
7 >10,240 160 65,535 7,179 2,198 >5,120 640 40
8 5,120 320 65,535 55,826 2,412 >5,120 1,280 160
9 5,120 >5,120 65,535 65,535 2,087 >5,120 1,280 320
10 >10,240 320 65,535 22,695 2,303 >5,120 1,280 320
11 5,120 1,280 65,535 28,391 2,858 >5,120 640 40

*rIFA, recombinant immunofluorescence assay (antigen used was complete spike protein); RFU, relative fluorescence units; vIFA, Middle East respiratory syndrome coronavirus–based immunofluorescence assay (antigen used complete virus); MERS-S, spike protein from Middle East respiratory syndrome coronavirus; OC43-S, spike protein from human coronavirus OC34; SARS-S, spike protein from severe acute respiratory syndrome virus; MERS-CoV, Middle East respiratory syndrome coronavirus; BCoV, bovine coronavirus; –, negative.
†Serum dilutions started at 1:20.
‡Assay was used for screening purposes.
§RFU <4,000 were considered negative. The serum dilution used in this assay was 1:20 (antigen used was S1 subunit of spike protein).
¶Serum dilutions started at 1:40.
#Assay applied for confirmation purposes.

Main Article

Page created: March 12, 2014
Page updated: March 12, 2014
Page reviewed: March 12, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external